DBS-LC-MS/MS assay for caffeine: Validation and neonatal application

Matteo Bruschettini; Sebastiano Barco; Olga Romantsik; Francesco Risso; Iulian Gennai; Benito Chinea; Luca A. Ramenghi; Gino Tripodi; Giuliana Cangemi

doi:10.4155/bio-2016-0127

DBS-LC-MS/MS assay for caffeine: Validation and neonatal application

Matteo Bruschettini, Sebastiano Barco, Olga Romantsik, Francesco Risso, Iulian Gennai, Benito Chinea, Luca A. Ramenghi, Gino Tripodi, Giuliana Cangemi

Neonatology

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: DBS might be an appropriate microsampling technique for therapeutic drug monitoring of caffeine in infants. Nevertheless, its application presents several issues that still limit its use. This paper describes a validated DBS-LC-MS/MS method for caffeine. Results: The results of the method validation showed an hematocrit dependence. In the analysis of 96 paired plasma and DBS clinical samples, caffeine levels measured in DBS were statistically significantly lower than in plasma but the observed differences were independent from hematocrit. Conclusion: These results clearly showed the need for extensive validation with real-life samples for DBS-based methods. DBS-LC-MS/MS can be considered to be a good alternative to traditional methods for therapeutic drug monitoring or PK studies in preterm infants.

Original language	English
Pages (from-to)	1893-1902
Number of pages	10
Journal	Bioanalysis
Volume	8
Issue number	18
DOIs	https://doi.org/10.4155/bio-2016-0127
Publication status	Published - 2016 Sept 1

Subject classification (UKÄ)

Gynaecology, Obstetrics and Reproductive Medicine
Pediatrics

Free keywords

caffeine
DBS
LC-MS/MS
newborn
PK
preterm
therapeutic drug monitoring

Access to Document

10.4155/bio-2016-0127

Cite this

@article{01bede13133d4041a107e17effa2d6d2,

title = "DBS-LC-MS/MS assay for caffeine: Validation and neonatal application",

abstract = "Aim: DBS might be an appropriate microsampling technique for therapeutic drug monitoring of caffeine in infants. Nevertheless, its application presents several issues that still limit its use. This paper describes a validated DBS-LC-MS/MS method for caffeine. Results: The results of the method validation showed an hematocrit dependence. In the analysis of 96 paired plasma and DBS clinical samples, caffeine levels measured in DBS were statistically significantly lower than in plasma but the observed differences were independent from hematocrit. Conclusion: These results clearly showed the need for extensive validation with real-life samples for DBS-based methods. DBS-LC-MS/MS can be considered to be a good alternative to traditional methods for therapeutic drug monitoring or PK studies in preterm infants.",

keywords = "caffeine, DBS, LC-MS/MS, newborn, PK, preterm, therapeutic drug monitoring",

author = "Matteo Bruschettini and Sebastiano Barco and Olga Romantsik and Francesco Risso and Iulian Gennai and Benito Chinea and Ramenghi, \{Luca A.\} and Gino Tripodi and Giuliana Cangemi",

year = "2016",

month = sep,

day = "1",

doi = "10.4155/bio-2016-0127",

language = "English",

volume = "8",

pages = "1893--1902",

journal = "Bioanalysis",

issn = "1757-6180",

publisher = "Taylor \& Francis",

number = "18",

}

TY - JOUR

T1 - DBS-LC-MS/MS assay for caffeine

T2 - Validation and neonatal application

AU - Bruschettini, Matteo

AU - Barco, Sebastiano

AU - Romantsik, Olga

AU - Risso, Francesco

AU - Gennai, Iulian

AU - Chinea, Benito

AU - Ramenghi, Luca A.

AU - Tripodi, Gino

AU - Cangemi, Giuliana

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Aim: DBS might be an appropriate microsampling technique for therapeutic drug monitoring of caffeine in infants. Nevertheless, its application presents several issues that still limit its use. This paper describes a validated DBS-LC-MS/MS method for caffeine. Results: The results of the method validation showed an hematocrit dependence. In the analysis of 96 paired plasma and DBS clinical samples, caffeine levels measured in DBS were statistically significantly lower than in plasma but the observed differences were independent from hematocrit. Conclusion: These results clearly showed the need for extensive validation with real-life samples for DBS-based methods. DBS-LC-MS/MS can be considered to be a good alternative to traditional methods for therapeutic drug monitoring or PK studies in preterm infants.

AB - Aim: DBS might be an appropriate microsampling technique for therapeutic drug monitoring of caffeine in infants. Nevertheless, its application presents several issues that still limit its use. This paper describes a validated DBS-LC-MS/MS method for caffeine. Results: The results of the method validation showed an hematocrit dependence. In the analysis of 96 paired plasma and DBS clinical samples, caffeine levels measured in DBS were statistically significantly lower than in plasma but the observed differences were independent from hematocrit. Conclusion: These results clearly showed the need for extensive validation with real-life samples for DBS-based methods. DBS-LC-MS/MS can be considered to be a good alternative to traditional methods for therapeutic drug monitoring or PK studies in preterm infants.

KW - caffeine

KW - DBS

KW - LC-MS/MS

KW - newborn

KW - PK

KW - preterm

KW - therapeutic drug monitoring

UR - https://www.scopus.com/pages/publications/84984710567

U2 - 10.4155/bio-2016-0127

DO - 10.4155/bio-2016-0127

M3 - Article

C2 - 27532249

AN - SCOPUS:84984710567

SN - 1757-6180

VL - 8

SP - 1893

EP - 1902

JO - Bioanalysis

JF - Bioanalysis

IS - 18

ER -

DBS-LC-MS/MS assay for caffeine: Validation and neonatal application

Abstract

Subject classification (UKÄ)

Free keywords

Access to Document

Other files and links

Fingerprint

Cite this